Q2 Earnings Beat: Social media commentary centered on Bausch Health's solid second-quarter results, where revenue and adjusted earnings exceeded analyst forecasts. The stock climbed sharply following the report, with observers noting accelerated growth in key segments like Salix. Management also raised full-year guidance amid broader healthcare sector momentum.
Long-Term Outlook: Discussions also touched on challenges ahead, including the 2028 patent loss for Xifaxan and potential impacts from price negotiations. Participants highlighted the firm's aggressive debt paydown using strong cash flows as a positive step. Overall views reflected short-term gains tempered by structural headwinds in the coming years.
Note: This discussion summary was generated from an AI condensation of post data.
Bausch Health Insider Trading Activity
Bausch Health insiders have traded $BHC stock on the open market 4 times in the past 6 months. Of those trades, 0 have been purchases and 4 have been sales.
Here’s a breakdown of recent trading of $BHC stock by insiders over the last 6 months:
- FRANK D. LEE sold 24,456 shares for an estimated $132,796
- SEANA CARSON (EVP, General Counsel) has made 0 purchases and 3 sales selling 19,664 shares for an estimated $115,039.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
Bausch Health Revenue
Bausch Health had revenues of $2B in Q2 2026. This is a decrease of -20.66% from the same period in the prior year.
You can track BHC financials on Quiver Quantitative's BHC stock page.
You can access data on BHC stock through the Quiver Quantitative API.
Bausch Health Hedge Fund Activity
We have seen 91 institutional investors add shares of Bausch Health stock to their portfolio, and 91 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- NATIONAL BANK OF CANADA /FI/ removed 4,931,952 shares (-92.8%) from their portfolio in Q1 2026, for an estimated $26,632,540
- NUVEEN, LLC added 3,464,801 shares (+1036.9%) to their portfolio in Q1 2026, for an estimated $18,709,925
- ACADIAN ASSET MANAGEMENT LLC added 2,669,082 shares (+120.8%) to their portfolio in Q1 2026, for an estimated $14,413,042
- GEODE CAPITAL MANAGEMENT, LLC added 2,505,189 shares (+145.3%) to their portfolio in Q1 2026, for an estimated $13,528,020
- ROYAL BANK OF CANADA added 2,262,894 shares (+24.9%) to their portfolio in Q1 2026, for an estimated $12,219,627
- GENDELL JEFFREY L added 1,671,565 shares (+128.8%) to their portfolio in Q1 2026, for an estimated $9,026,451
- ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 1,528,438 shares (-56.1%) from their portfolio in Q1 2026, for an estimated $8,253,565
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
Bausch Health Price Targets
Multiple analysts have issued price targets for $BHC recently. We have seen 2 analysts offer price targets for $BHC in the last 6 months, with a median target of $8.0.
Here are some recent targets:
- Douglas Miehm from RBC Capital set a target price of $9.0 on 04/27/2026
- Glen Santangelo from Barclays set a target price of $7.0 on 02/25/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
